The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
Zhuoer Xie(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Susan M. Geyer(Mayo Clinic in Florida), Lionel Adès(Délégation Paris 7), Andrew M. Brunner(Harvard University), Rami S. Komrokji(Moffitt Cancer Center), Yasmin Abaza(Northwestern University), Hetty E. Carraway(Cleveland Clinic), Charlton Tsai(NewYork–Presbyterian Hospital), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Cecilia Arana Yi(Mayo Clinic Hospital), James M. Foran(Memorial Sloan Kettering Cancer Center), Anand Patel(Ascension), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Eric Padron(Moffitt Cancer Center), Abhay Singh(Cleveland Clinic), Monzr M. Al Malki(City of Hope), Michael R. Savona(Vanderbilt University), Alexandra N. Smith(Vanderbilt University Medical Center), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Catherine Lai(University of Pennsylvania), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), Najla Al Ali(Moffitt Cancer Center), Shira Dinner(Dana-Farber Cancer Institute), Amer M. Zeidan(Yale Cancer Center), Mrinal M. Patnaik(Mayo Clinic), Pinkal Desai(NewYork–Presbyterian Hospital), Talha Badar(Mayo Clinic in Florida), Deborah Soong(University of Miami), Idoroenyi Amanam(City Of Hope National Medical Center), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Justin Taylor(Medical University of South Carolina), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Caner Saygin(University of Illinois Chicago), Joachim Deeg(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Afaf E.G. Osman(University of Utah)
Cited by 6
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k